Keymed Biosciences Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	503.35	418.41	851.03	604.07	1,521
Short-Term Investments	1,100	1,737	1,694	2,339	1,951
Trading Asset Securities	319.94	0.24	174.37	232.19	53.4
Cash & Short-Term Investments	1,924	2,156	2,719	3,175	3,525
Cash Growth	-10.76%	-20.73%	-14.37%	-9.91%	895.41%
Accounts Receivable	100.85	63.73	27.97	0.48	10.55
Other Receivables	61.1	51.02	18.5	34.01	0.72
Receivables	161.95	114.75	46.47	34.49	11.27
Inventory	212.33	123.97	61.1	51.33	22.43
Restricted Cash	39.59	-	1.78	-	-
Other Current Assets	85.22	71.7	111	48.83	23.67
Total Current Assets	2,423	2,466	2,940	3,310	3,582
Property, Plant & Equipment	1,299	1,048	893.74	584.43	177.53
Long-Term Investments	420.14	210.03	21.63	20.57	20.28
Other Intangible Assets	8.07	9.75	1.11	1.5	1.1
Other Long-Term Assets	67.17	32.66	26.91	15.84	153.59
Total Assets	4,218	3,767	3,883	3,932	3,934
Accounts Payable	28.06	26.01	29.49	14.91	2.78
Accrued Expenses	162.62	123.36	113.2	90.99	49.93
Short-Term Debt	344.02	337.18	13.01	60.79	0.55
Current Portion of Long-Term Debt	165.35	135.19	32.81	0.6	-
Current Portion of Leases	9.52	12.36	19.43	11.08	11.72
Current Income Taxes Payable	2.73	-	1.82	1.03	0.94
Current Unearned Revenue	0.45	1.58	-	-	1.61
Other Current Liabilities	123.55	112.05	104.42	200.3	44.54
Total Current Liabilities	836.29	747.73	314.18	379.7	112.08
Long-Term Debt	258.03	257.19	331.83	28.8	-
Long-Term Leases	11.62	11.32	21.62	20.93	26.99
Long-Term Unearned Revenue	336.67	274.78	228.19	163.67	8.72
Long-Term Deferred Tax Liabilities	-	0.35	0.28	-	-
Other Long-Term Liabilities	-	-	-	-	141.29
Total Liabilities	1,443	1,291	896.11	593.1	289.07
Common Stock	0.2	0.17	0.17	0.17	0.17
Additional Paid-In Capital	9,326	8,496	8,484	8,485	8,516
Retained Earnings	-6,687	-6,165	-5,649	-5,290	-4,982
Treasury Stock	-0	-0	-	-	-
Comprehensive Income & Other	135.36	143.07	151.76	144.97	116.82
Total Common Equity	2,774	2,475	2,986	3,340	3,651
Minority Interest	0.67	0.64	0.5	-1.07	-5.59
Shareholders' Equity	2,775	2,475	2,987	3,339	3,645
Total Liabilities & Equity	4,218	3,767	3,883	3,932	3,934
Total Debt	788.54	753.24	418.71	122.19	39.26
Net Cash (Debt)	1,135	1,402	2,300	3,053	3,485
Net Cash Growth	-19.05%	-39.04%	-24.65%	-12.40%	-
Net Cash Per Share	4.14	5.35	8.80	11.69	21.67
Filing Date Shares Outstanding	294.6	275.6	276.6	277.39	279.74
Total Common Shares Outstanding	294.6	275.6	276.6	277.39	279.74
Working Capital	1,587	1,718	2,625	2,930	3,470
Book Value Per Share	9.42	8.98	10.80	12.04	13.05
Tangible Book Value	2,766	2,465	2,985	3,339	3,650
Tangible Book Value Per Share	9.39	8.94	10.79	12.04	13.05
Buildings	250.7	190.16	190.16	-	-
Machinery	734.05	692.07	626.77	235.49	110.64
Construction In Progress	449.82	213.93	34.48	323.55	21.63
Leasehold Improvements	60.41	62.05	60.77	51.73	42.45

Source: S&P Global Market Intelligence. Standard template. Financial Sources.